DOCSLIB.ORG

Lawrence O. Gostin CV

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

LAWRENCE O. GOSTIN Curriculum Vitae Phone: +1 202 662-9373 Georgetown University Law Center Email: [email protected] 600 New Jersey Ave., NW Washington, DC 20001 WEBSITES INTERNET RESOURCES Autobiographical Article: From a Civil Libertarian to a Sanitarian, 34 J. LAW & SOCIETY 594- 616 (Dec 2007) The Lancet Profile: Lawrence Gostin: Legal Activist in the Cause of Global Health, 386 THE LANCET 2133 (Nov 28, 2015). Faculty Profile O’Neill Institute for National and Global Health Law: Global Health & Human Rights Database, in partnership with the WHO and Lawyers’ Collective of India. O’Neill Institute, Prof. Gostin’s Health Tips Georgetown Law Faculty Profile SCHOLARLY PRODUCTIVITY AND IMPACT A systematic empirical analysis of legal scholarship, independent researchers ranked Prof. Gostin 1st in the nation in productivity among all law professors, and 11th in impact and influence. In 2017, researchers ranked Professor Gostin 1st in the nation in citations for health law. Prof. Gostin is also ranked first among health law professors on Google Scholar and on West Law (2018). He is in the top 10% worldwide for downloads on SSRN. MAJOR GLOBAL HEALTH CAMPAIGNS THE JOINT ACTION AND LEARNING INITIATIVE: TOWARDS A FRAMEWORK CONVENTION ON GLOBAL HEALTH In 2008, at the founding of the O’Neill Institute, Prof. Gostin proposed a Framework Convention on Global Health founded on the right to health, published in the Georgetown Law Journal. A decade later, in 2018, civil society organizations from every region of the world launched the Framework Convention on Global Health Alliance. The groundwork for the Alliance had been laid by the Joint Action and Learning Initiative on National and Global Responsibilities for Health and the Platform for an FCGH. The World Health Report 2010 featured the FCGH, and the Global Health Governance journal featured a FCGH symposium in 2016. Stakeholder meetings have been held in Oslo, Berlin, Johannesburg, Delhi, Bellagio, Kampala, and Dhaka, among others. In 2011, UN Secretary-General Ban Ki-moon endorsed the FCGH: “Let the AIDS response be a beacon of global solidarity for health as a human right and set the stage for a future United Nations Framework Convention on Global Health.” UNAIDS Director, Michel Sidibé urged human rights advocates to ”Join the FCGH movement for social justice.” GLOBAL COMMISSIONS ON THE 2015 WEST AFRICA EBOLA EPIDEMIC CURRICULUM VITAE, LAWRENCE O. GOSTIN, P. 2 Professor Gostin served three global commissions on the lessons learned from the 2015 West Africa Ebola epidemic: The Commission on a Global Health Risk Framework (National Academy of Medicine); Independent Panel on the Global Response to Ebola (Harvard/London School of Hygiene and Tropical Medicine); and the United Nations High-Level Panel on Global Response to Health Crises. EMPLOYMENT • University Professor (Georgetown University’s • Professor of Global Health Law in the Faculty of highest academic rank conferred by the Law, University of Sydney University President) • Visiting Professor and the Claude Leon • Linda D. and Timothy J. O’Neill Professor of Foundation Distinguished Scholar, The Global Health Law, Georgetown University Law University of the Witwatersrand, Johannesburg, Center (2007-2012) South Africa (2011/12) (Academic Honor: Nobel • Faculty Director, Linda D. and Timothy J. Laureate Selection Criteria) O’Neill Institute for National and Global Health • Professor of Law & Public Health, The Johns Law Hopkins University, Bloomberg School of Public • Director, World Health Organization Health, 1997-2013 Collaborating Center on National and Global • Faculty Director, LL.M Program in Global Health Law (the health and human rights global Health Law, Georgetown University database is illustrative of the projects launched by • Faculty Director, LL.M Program in Global the WHO Collaborating Center) Health Law and International Institutions, • National Cancer Advisory Board (Presidential Georgetown Law and The Graduate Institute of Appointment) Geneva • Co-Principal Investigator, FDA Center of • Faculty Affiliate, Kennedy Institute of Ethics, Excellence in Regulatory Science and Innovation Georgetown University (CERSI), 2014-17. • Research Fellow, Centre for Socio-Legal Studies, • Professor, Department of Microbiology and Faculty of Law, University of Oxford Immunology, Georgetown University School of • Visiting Professor of Public Health Faculty of Medicine Medical Sciences, Oxford University (July 1, • Associate Dean (Research and Academic 2005 – June 30, 2013) Programs) Georgetown University Law Center • Visiting Professor of Global Health and (Responsible for faculty research and International Visiting Fellow, University of scholarship), 2005-2008 Sydney, 2009 • John Carroll Research Professor (2004/05) • Miegunyah Distinguished Visiting Fellow, Georgetown University Law Center University of Melbourne and Senior Fellow, • Director, Center for Law & the Public’s Health at Melbourne Law School, 2009 – 2022. Georgetown and Johns Hopkins Universities • University of Manchester (Institute for Science, (CDC Collaborating Center) (1995-2010). Ethics and Innovation), Visiting Professorial • Global Health Editor & Legal Correspondent, Fellow, 2011 Journal of the American Medical Association EDUCATION 1971 STATE UNIVERSITY OF NEW YORK AT BROCKPORT B.A. (Psychology, Summa Cum Laude) CURRICULUM VITAE, LAWRENCE O. GOSTIN, P. 3 1974 DUKE UNIVERSITY SCHOOL OF LAW J.D. 1974-75 OXFORD UNIVERSITY AND THE SOCIAL RESEARCH UNIT, UNIVERSITY OF LONDON Fulbright Fellow, United Kingdom, in Psychiatry and Law 1994 STATE UNIVERSITY OF NEW YORK (system-wide), Doctor of Laws (Honoris Causa) EDUCATION (CONTINUED) 2006 CARDIFF UNIVERSITY, WALES Honorary Fellow (University’s highest honor for “international distinction and scholarship in law and public health”) 2007 FELLOW OF THE ROYAL SOCIETY FOR PUBLIC HEALTH (FSPH) 2012 THE UNIVERSITY OF SYDNEY Doctor of Laws (Honoris Causa) Delivered Commencement Address to the Sydney Law Class of 2012 PAST POSITIONS • Visiting Professor, Di Tella School of Law, • Vice Chair, Committee on the Use of Human Buenos Aires (2017) Subjects in Research Harvard School of Public • Visiting Scholar, Centre for Socio-Legal Studies Health (1991-93) Oxford University (2002) • Visiting Fellow, Centre for Socio-Legal Studies • Member, President’s Task Force on National Wolfson College, Oxford University (Summer, Health Care Reform Chair, Health Information 1989) Privacy Chair, Public Health (1993-94) • Legislative Counsel, Labor and Human • Executive Director, American Society of Law, Resources Committee, Edward Kennedy, Medicine & Ethics (1986-1994) Chairman United States Senate (1987-88) • Adjunct Professor of Law & Public Health In the • General Secretary (Chief Executive), National faculty of Public Health, Harvard University Council for Civil Liberties (U.K.) (1983-85) formerly Senior Fellow, Lecturer, and Adjunct • Fellow in Psychiatry and Law, Centre for Associate Professor (1985-94) Criminological Research, Oxford University • Associate Director, International Collaborating (1982-83) Associate (1983-85) Center on Health Legislation Harvard • Legal Director, MIND (National Association for University/World Health Organization (1988-94) Mental Health) (U.K.) (1975-82) • Lecturer on Law In the Faculty of Law, Harvard Law School (1989-93) PROFESSIONAL AND BAR ASSOCIATIONS • Member New York State Bar Association (1981- • Member Bar of the Council of Europe (European present) Commission and European Court of Human Rights) (1977-present) CURRICULUM VITAE, LAWRENCE O. GOSTIN, P. 4 HONORS/RECOGNITIONS • Rosemary Delbridge Memorial Award from the • The Adam Yarmolinsky Medal conferred by the National Consumer Council (U.K.) for the person National Academy of Sciences for “distinguished “who has most influenced Parliament and service by a Member who, over a significant government to act for the welfare of society” period of time, has contributed in multiple ways (1983). to the mission of the Institute of Medicine.” • Lifetime Elected Member, National Academy of (2006). Medicine, of the National Academies of • Distinguished Lifetime Achievement Award from Sciences, Engineering, and Medicine (formerly the Public Health Law Association presented at Institute of Medicine). the National CDC Public Health Law • Lifetime Elected Fellow, The Hastings Center: Conference: “in recognition of a career devoted “For individuals who have made distinguished to using law to improve the public’s health” contributions to the field of bioethics.” (2006). • Lifetime Elected Member, Council on Foreign • Key to Tohoko University, Japan, for Relations (to provide independent advice to distinguished contributions to human rights in governments on foreign policy). mental health (January 1987). • Lifetime Achievement Award by the American • Public Service Award from the State University Public Health Association (APHA) for a career of New York for distinguished public service and devoted to Public Health Law (2015). professional accomplishment (1991). • Distinguished Lifetime Achievement Award, • State University of New York, Hall of Heritage Public Health Association of New York City, for (2005) a for “most outstanding success in his/her extraordinary service to improve the public’s profession and significant contribution to higher health (2014). education or public service.” • Dr. Mary Ann Quaranta Distinguished Public • Jay Healy Health Law Teacher of the Year, Health Law Scholar Award, Bestowed by the conferred by the American Society
Recommended publications
  • Using the COVID-19 Pandemic to Reimagine Global Health Teaching in High-Income Countries

    Using the COVID-19 Pandemic to Reimagine Global Health Teaching in High-Income Countries

    Editorial Using the COVID-19 pandemic to BMJ Glob Health: first published as 10.1136/bmjgh-2021-005649 on 1 April 2021. Downloaded from reimagine global health teaching in high- income countries 1,2 3 4 5,6 Salla Atkins, Ananya Tina Banerjee, Kathleen Bachynski, Amrita Daftary , Gauri Desai,7 Aeyal Gross,8 Bethany Hedt- Gauthier,9 Emily Mendenhall,10 Benjamin Mason Meier,11,12 Stephanie A Nixon,13 Ann Nolan,14 Tia M Palermo,7 Alexandra Phelan,15 Oksana Pyzik,16 Pamela Roach,17 Thurka Sangaramoorthy,18 15 19 20 21 Claire J. Standley, Gavin Yamey , Seye Abimbola , Madhukar Pai To cite: Atkins S, Banerjee AT, INTRODUCTION educate students to address health disparities Bachynski K, et al. Using The COVID-19 pandemic has changed how wherever they occur, not just in LMICs. While the COVID-19 pandemic to reimagine global health we live, work and communicate. Global health the online format offers many challenges, teaching in high- income teaching is no exception. Across universities, we believe there are ways to increase student countries. BMJ Global Health professors like us have had to quickly rede- engagement and reduce fatigue (box 2). 2021;6:e005649. doi:10.1136/ sign our courses, and deliver them virtually, bmjgh-2021-005649 even as the pandemic continues to bring new challenges every day. Out of that struggle, USE COVID-19 AS A TEACHABLE MOMENT Received 8 March 2021 Even before the pandemic, students in HICs new learning opportunities have emerged. 2 Accepted 11 March 2021 This editorial, coauthored by 20 professors have shown great interest in global health.
  • A Menace Wrapped in a Protein: Zika and the Global Health Security Agenda

    A Menace Wrapped in a Protein: Zika and the Global Health Security Agenda

    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/320677119 Title: A MENACE WRAPPED IN A PROTEIN: ZIKA AND THE GLOBAL HEALTH SECURITY AGENDA Technical Report · September 2017 DOI: 10.13140/RG.2.2.25050.85443 CITATIONS READS 2 129 5 authors, including: Helen Epstein Wilmot James Bard College Columbia University 28 PUBLICATIONS 925 CITATIONS 5 PUBLICATIONS 15 CITATIONS SEE PROFILE SEE PROFILE Ángel G Muñoz Lawrence Stanberry Columbia University Columbia University 121 PUBLICATIONS 694 CITATIONS 238 PUBLICATIONS 7,326 CITATIONS SEE PROFILE SEE PROFILE Some of the authors of this publication are also working on these related projects: Climate informed malaria prevention, control and elimination View project ENACTS (Enhanced National Climate Services) View project All content following this page was uploaded by Ángel G Muñoz on 27 October 2017. The user has requested enhancement of the downloaded file. Title: A MENACE WRAPPED IN A PROTEIN: ZIKA AND THE GLOBAL HEALTH SECURITY AGENDA Authors: Helen Epstein, Wilmot James, Ángel G. Muñoz, Lawrence Stanberry & Madeleine C. Thomson. Reference: Columbia GHS&D Working Group Papers 2017-01 Date: September, 2017 Place: Columbia University Medical Center, Morgan Stanley Children’s Hospital, Office 102, 3959 Broadway CHC 1-102, New York City NY 10032, USA. Copyright: This work is licensed under the Creative Commons Attribution-NonCommercial- ShareAlike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/. A MENACE WRAPPED IN A PROTEIN1: ZIKA AND THE GLOBAL HEALTH SECURITY AGENDA Preface Stephen Nicholas & Marc Grodman… i 1.Zika: Implications for Global Health Security Helen Epstein… 1 2.Zika Pathogenesis, Diagnosis and Vaccines Lawrence Stanberry… 12 3.Climate Change, the Environment and the Zika Outbreak Madeleine C.
  • The COVID-19 Infodemic* 07 08

    The COVID-19 Infodemic* 07 08

    01 Editorial 02 03 04 05 06 The COVID-19 Infodemic* 07 08 1 1 2 3 4 09 Sebastián García-Saisó, Myrna Marti, Ian Brooks, Walter H. Curioso, Diego González, 10 Victoria Malek,1 Felipe Mejía Medina,1 Carlene Radix,5 Daniel Otzoy,6 Soraya Zacarías,7 11 1 1 12 Eliane Pereira dos Santos and Marcelo D’Agostino 13 14 15 16 Suggested citation García-Saisó S, Marti M, Brooks I, Curioso WH, González D, Malek V, et al. The COVID-19 Infodemic. Rev Panam Salud Publica. 2021;45:e56. https://doi.org/10.26633/RPSP.2021.56 17 18 19 20 On 15 February 2020, during the Munich Security Conference The infodemic can negatively impact health and well-being 21 (1), the Director of the World Health Organization (WHO), Dr. and can also polarize public debate. Campaigns against public 22 Tedros Adhanom Ghebreyesus, stated that the fight against health measures, inaccurate or falsified epidemiological data, and 23 the COVID-19 pandemic was accompanied by a fight against fake or biased evidence can potentially alter people’s behavior. 24 an “infodemic”, leading to a series of initiatives by the WHO This puts extra pressure on health systems, as it undermines the 25 and other organizations to face this challenge. This situation is scope and efficiency of the various health intervention programs. 26 not new: others have occurred during other health emergen- The main factors contributing to the development of the info- 27 cies, but never one of the current magnitude, resulting from the demic are associated with a lack of digital literacy programs (5) 28 increased use of digital applications (2).
  • Covid and That Other Pandemic—Lies T’S Been a Long Weekend

    Covid and That Other Pandemic—Lies T’S Been a Long Weekend

    comment “NHS staff's TikTok dances are feeding the hostile social media beast” DAVID OLIVER “To establish trust, we need transparency and everyday language” HELEN SALISBURY PLUS Covid’s impact on defensive medicine; a child’s right not to be hit CRITICAL THINKING Matt Morgan Covid and that other pandemic—lies t’s been a long weekend. The growing number must also speak no evil. Instead, they scream it at of my colleagues self-isolating has led to the top of their lungs. Half of the profi les pushing the increasing gaps in our rota. Combined with the unethical, dangerous, and discredited case for herd unwelcome return of covid-19 to intensive care immunity through the Great Barrington Declaration Iunits throughout Europe, the long hard summer were artifi cial, bot-like accounts, amplifi ed by social is morphing into the longer, harder winter. I let out a media above the consensus view. slow exhale as I sink into my sofa after arriving home As doctors, nurses, and patients, we must move late on a Sunday night. Time to recharge, relax, and beyond blaming individuals who respond to these refl ect—but a million voices are shouting at me. bad ideas and bad incentives: instead, let us task A video on YouTube tells me that the covid tests I the companies with taking responsibility for their ordered were false. A Facebook post proclaims that output. If not, they can fund the intensive care masks are simply a tool of government oppression. beds, the staff sickness gaps, and the tissues Twitter advises me that those death certifi cates I’ve to wipe away tears when their broadcast written were lies.
  • COVID-19 Speaker Key: MH Dr Margaret Harris TAG Dr Tedros

    COVID-19 Speaker Key: MH Dr Margaret Harris TAG Dr Tedros

    COVID-19 Speaker key: MH Dr Margaret Harris TAG Dr Tedros Adhanom Ghebreyesus TU Tu MR Dr Michael Ryan VA Vadia MK Dr Maria Van Kerkhove DI Diego IM Imogen CR Charles CO Corinne CS Costas MH Good morning, afternoon and evening. Welcome, everybody, and thank you for joining this latest WHO press briefing on COVID-19. As most of you are aware, we here at WHO headquarters in Geneva are practising physical distancing as one measure to stop COVID-19 transmission so from this week and onwards these press briefings will be held as virtual meetings with very few of us in the room. You can see we're well apart. Just some housekeeping; if you've joined online please use the raise your hand icon to indicate you want to ask a question. If you've joined by phone press # 9 on your keypad to ask a question. Listen out for your name. Sometimes names are not clear when we get them so my apologies in advance. We have here today three people who for most of you need no introduction. We have WHO director-general, Dr Tedros, our executive director of our emergency programme, Dr Mike Ryan, and our technical lead, Dr Maria Van Kerkhove. Dr Tedros will provide some opening remarks, then we'll open it for questions. I'd like to remind you we can only have one question per journalist. We've got limited time. This is a very busy time for everybody so please respect that. There are a lot of you and we want to give everybody a fair chance.
  • COVID-19 Vaccination Strategy in China: a Case Study

    COVID-19 Vaccination Strategy in China: a Case Study

    Article COVID-19 Vaccination Strategy in China: A Case Study Marjan Mohamadi 1,†, Yuling Lin 1,*,† ,Mélissa Vuillet Soit Vulliet 1,†, Antoine Flahault 1, Liudmila Rozanova 1 and Guilhem Fabre 2 1 Institute of Global Health, University of Geneva, 1211 Geneva, Switzerland; [email protected] (M.M.); [email protected] (M.V.S.V.); antoine.fl[email protected] (A.F.); [email protected] (L.R.) 2 Department of Chinese, UFR 2, Université Paul Valéry Montpellier 3, 34199 Montpellier, France; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: The coronavirus disease 2019 (COVID-19) outbreak in China was first reported to the World Health Organization on 31 December 2019, after the first cases were officially identified around 8 December 2019. However, the case of an infected patient of 55 years old can probably be traced back on 17 November. The spreading has been rapid and heterogeneous. Economic, political and social impacts have not been long overdue. This paper, based on English, French and Chinese research in national and international databases, aims to study the COVID-19 situation in China through the management of the outbreak and the Chinese response to vaccination strategy. The coronavirus disease pandemic is under control in China through non-pharmaceutical interventions, and the mass vaccination program has been launched to further prevent the disease and progressed steadily with Citation: Mohamadi, M.; Lin, Y.; 483.34 million doses having been administered across the country by 21 May 2021. China is also Vulliet, M.V.S.; Flahault, A.; acting as an important player in the development and production of SARS-CoV-2 vaccines.
  • NOV 2020 RR Updated CREAM.Indd

    NOV 2020 RR Updated CREAM.Indd

    RESEARCH REPORTS Volume LXXXI November 2020 published by RESEARCH REPORTS AIER publishes over 100 articles per month that are distributed in digital form. Research Reports contains Business Conditions Monthly plus 12 of the most representative, chosen here for popularity, variety, and relevance. These articles are often reprinted in venues around the web, including Seeking Alpha, Intellectual Takeout, Mises Brasil, and dozens of other outlets. To read all of them, go to www.aier.org Business Conditions Monthly ROBERT HUGHES 1 The Year of Disguises ROGER W. KOOPS 9 AIER Hosts Top Epidemiologists, Authors of the Great Barrington Declaration AIER STAFF 20 The Great Barrington Declaration and Its Critics JENIN YOUNES 22 Reddit’s Censorship of The Great Barrington Declaration ETHAN YANG 25 The Sketchy Claims of the Case for a Mask Mandate PHILLIP W. MAGNESS 28 Lockdown: The New Totalitarianism JEFFREY A. TUCKER 32 What’s Behind The WHO’s Lockdown Mixed-Messaging STACEY RUDIN 35 Covid Is Not Categorically Different DONALD J. BOUDREAUX 41 The Devastating Economic Impact of Covid-19 Shutdowns AMELIA JANASKIE & PETER C. EARLE 43 Will Things Ever Go Back To Normal? JOAKIM BOOK 53 Does Anyone Trust the Fed? THOMAS L. HOGAN 56 QE Goes Global COLIN LLOYD 58 BUSINESS CONDITIONS MONTHLY Robert Hughes Senior Research Fellow AIER’s Leading Indicators Index Improves Again in October The U.S. economy continued to recover in October from the historic plunge in economic activity in the first half of the year. However, the pace of recovery in some areas has slowed. Furthermore, fallout from continuing restrictions (small business and personal bankruptcies) as well as the potential for renewed lockdown policies remain ongoing threats to future growth.
  • The Covid–19 Pandemic and Haemoglobin Disorders

    The Covid–19 Pandemic and Haemoglobin Disorders

    THE COVID–19 PANDEMIC AND HAEMOGLOBIN DISORDERS VACCINATIONS & THERAPEUTIC DRUGS An Informational Guide from the Thalassaemia International Federation (TIF) Prepared by: Dr Androulla Eleftheriou, Executive Director, TIF Last Updated: 12 May 2020 VACCINATIONS & THERAPEUTIC DRUGS Introduction It is important to note that there are currently no FDA1 or EMA2-approved or even recommended agents for the treatment of the novel coronavirus (COVID-19), for which the World Health Organization (WHO) declared as pandemic on Wednesday 11th of March 2020. Any agent being used at this time is being administered in an experimental setting under controlled conditions. Thalassaemia International Federation (TIF) has made an effort to compile a list of studies/clinical trials for treatment and vaccines, which is by no means exhaustive as this situation is extremely labile and research in this area is dramatically intensified. New information is anticipated to be added to this guide which is prepared exclusively for TIF’s global thalassemia community. The viral genome was mapped very soon as rom early January 2020 and shared globally. In February 2020, the WHO published an overview of the potential therapeutic candidates for the treatment of COVID-19. The document outlines 76 regimens that have been proposed (as of February 17, 2020) for the treatment of patients infected with the virus. Thirty-eight of these candidates are in the preclinical state with minimal information available on their proposed mechanism, uses, doses routes, or planned trials. Sixteen of the remaining regimens contain an interferon-based product. The rest include a variety of antimicrobials, corticosteroids, convalescent plasma, and biologics. The Director-General of the WHO, Mr Tedros Adhanom, stated on the 10th of April 2020, that more than 70 countries have joined WHO’s trial to accelerate research on effective treatments and 20 Institutions and companies ‘are racing to develop a vaccine’.
  • Melbourne Law School Covid-19 Research Network

    Melbourne Law School Covid-19 Research Network

    MELBOURNE LAW SCHOOL COVID-19 RESEARCH NETWORK ANNOTATED BIBLIOGRAPHY OF COVID-19 LEGAL LITERATURE Updated 1 July 2020 Note: the annotated bibliography below is arranged A) Literature B) Organisations and C) Blogs, journals and websites. A briefer version of this bibliography, containing citations only, is available on the Melbourne Law School website at https://law.unimelb.edu.au/centres/hlen/covid-19/scholarship. The literature in Part A includes scholarship and selected professional literature and is divided into broad topics, beginning with general literature followed by specific topics. We have only included each article under one topic heading, even if it is appropriate to be listed in two or more topics. A note on the jurisdiction is included if this is not immediately obvious from the citation. We have only included literature written in English. Part B lists selected organisations with dedicated COVID-19 legal publications pages. Part C lists selected blogs or other online fora. This bibliography will be regularly updated. This bibliography was compiled by the Melbourne Law School Academic Research Service, using the following journal article databases: Index to Legal Periodicals (EBSCO), AGIS (INFORMIT), Westlaw UK Journals, Westlaw Canada Journals, HEIN, SSRN and Google Scholar. In order to publish scholarship quickly, many scholarly journals have introduced ways to fast-track publication, including a faster peer- review process, and publishing accepted manuscripts, so much of the scholarship listed is in its pre- publication form. Much pre-published scholarship is also available on open access on SSRN, which has a dedicated Coronavirus Hub for early stage non-peer reviewed research to help researchers freely share their latest research.
  • Icn at the 73Rd World Health Assembly, 2020 and the 148Th Who Executive Board, 2021

    Icn at the 73Rd World Health Assembly, 2020 and the 148Th Who Executive Board, 2021

    INTERNATIONAL COUNCIL OF NURSES ICN AT THE 73RD WORLD HEALTH ASSEMBLY, 2020 AND THE 148TH WHO EXECUTIVE BOARD, 2021 Prepared by Erica Burton - ICN Senior Advisor, Nursing & Health Policy TABLE OF CONTENTS INTRODUCTION .............................................................................................................3 OPENING OF THE RESUMED WHA73 ........................................................................3 Address by WHO Director-General Dr Tedros Adhanom Ghebreyesus WHA73 3 Keynote address by Her Royal Highness Princess Muna Al-Hussein of Jordan (HRH), WHO Patron for Nursing & Midwifery .........................................................4 OPENING OF THE EB148 ..............................................................................................5 Address by WHO Director-General Dr Tedros Adhanom Ghebreyesus .............5 COVID-19 response ..................................................................................................5 WHO’s work in health emergencies .......................................................................6 Strengthening WHO’s global emergency preparedness and response .......6 .....Strengthening preparedness for health emergencies: implementation of the International Health Regulations (2005) .................................................................7 Interim progress report of the Review Committee on the functioning of the International Health Regulations (2005) during the COVID-19 response ............7 Mental health preparedness and response for the COVID-19
  • Symptoms of a Broken System: the Gender Gaps in COVID-19 Decision-­ Making

    Symptoms of a Broken System: the Gender Gaps in COVID-19 Decision-­ Making

    Commentary BMJ Glob Health: first published as 10.1136/bmjgh-2020-003549 on 1 October 2020. Downloaded from Symptoms of a broken system: the gender gaps in COVID-19 decision- making 1,2 3 2 Kim Robin van Daalen , Csongor Bajnoczki, Maisoon Chowdhury, Sara Dada,2,4 Parnian Khorsand,2 Anna Socha,3 Arush Lal,2 Laura Jung,2,5 6 7 8,9 Lujain Alqodmani, Irene Torres , Samiratou Ouedraogo, 10,11 2 12 3 Amina Jama Mahmud, Roopa Dhatt, Alexandra Phelan, Dheepa Rajan To cite: van Daalen KR, A growing chorus of voices are questioning Summary box Bajnoczki C, Chowdhury M, the glaring lack of women in COVID-19 et al. Symptoms of a broken system: the gender gaps decision- making bodies. Men dominating ► Despite numerous global and national commit- in COVID-19 decision- leadership positions in global health has long ments to gender- inclusive global health governance, making. BMJ Global Health been the default mode of governing. This is COVID-19 followed the usual modus operandi –ex- 2020;5:e003549. doi:10.1136/ a symptom of a broken system where gover- cluding women’s voices. A mere 3.5% of 115 iden- bmjgh-2020-003549 nance is not inclusive of any type of diversity, tified COVID-19 decision- making and expert task be it gender, geography, sexual orientation, forces have gender parity in their membership while Handling editor Seye Abimbola race, socio-economic status or disciplines 85.2% are majority men. within and beyond health – excluding those ► With 87 countries included in this analysis, informa- Received 27 July 2020 tion regarding task force composition and member- Revised 22 August 2020 who offer unique perspectives, expertise and ship criteria was not easily publicly accessible for Accepted 24 August 2020 lived realities.
  • 9780520282650.Indd Iii 18/12/15 7:59 PM Chapter Eleven

    9780520282650.Indd Iii 18/12/15 7:59 PM Chapter Eleven

    Chapter 11 Excerpt Public Health Law Power, Duty, Restraint Third Edition Lawrence O. Gostin and Lindsay F. Wiley university of california press Gostin - 9780520282650.indd iii 18/12/15 7:59 PM chapter eleven Public Health Emergency Preparedness Terrorism, Pandemics, and Disasters Everybody knows that pestilences have a way of recurring in the world, yet somehow we fi nd it hard to believe in ones that crash down on our heads from a blue sky. There have been as many plagues as wars in history; yet always plagues and wars take people equally by surprise. —Albert Camus, The Plague, 1948 Terrorist attacks, novel infl uenzas, emerging infectious diseases, and natural disasters have prompted a reexamination of the nation’s public health system. The jetliner and anthrax attacks of 2001, the SARS out- break of 2003, hurricanes Rita and Katrina in 2005, the 2009 H1N1 infl uenza pandemic, Hurricane Irene in 2011, Hurricane Sandy in 2012, the Texas fertilizer plant explosion in 2013, and the West African Ebola epidemic in 2014–15 have focused attention on public health prepared- ness. In the years following the 2001 attacks, “the conceptual frame- work of emergency preparedness and response subsume[d] ever larger segments of the fi eld of public health.”1 The outpouring of resources and attention to biosecurity has supported a public health law renaissance. Perceived government failures in response to public health emergencies continue to stoke public anxiety, adding political pressure for more eff ective preparedness planning. All-hazards and resilience have become watchwords in preparedness.2 Vertical strategies targeting specifi c threats (e.g., development of patho- gen- or toxin-specifi c vaccines and treatments) remain a priority.